araag2/HINT huggingface dataset:
Clinical trial NCT02437487 (phase 2, status: completed)
Conditions: clostridium difficile
ICD codes: A04.71, A04.72
Drugs: ser-109, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Signed informed consent, indicating that the patient understands the purpose of and
             procedures required for the study. Patients who are unable to provide informed consent
             will not be included in the study.

          2. Male or female patients ≥ 18 years.

          3. ≥ 3 episodes of CDI within the previous 9 months, inclusive of the current episode
             with documentation of ≥ 2 episodes.

        Exclusion Criteria:

          1. Female patients who are pregnant, breastfeeding, lactating, or planning to become
             pregnant during the study.

          2. Known or suspected toxic megacolon and/or known small bowel ileus.

          3. Active irritable bowel syndrome with diarrhea within the previous 12 months.

          4. Major gastrointestinal surgery (eg, significant bowel resection or diversion) within 3
             months before enrollment (this does not include appendectomy or cholecystectomy) or
             any history of total colectomy or bariatric surgery.

          5. History of inflammatory bowel disease (ulcerative colitis, Crohn's disease,
             microscopic colitis) with diarrhea believed to be caused by active inflammatory bowel
             disease in the past 24 months.

          6. Admitted to or expected to be admitted to an acute care facility or intensive care
             unit for medical reasons (not just boarding). Patients discharged from an acute care
             facility before Day 1 or residing in nursing homes or rehabilitation facilities may be
             enrolled.

          7. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for
             active malignancy (patients on maintenance chemotherapy may only be enrolled after
             consultation with medical monitor).
Clinical trial NCT02440178 (phase 2, status: completed)
Conditions: acute leukemia
ICD codes: C91.01, C91.02, C92.01, C92.02, C92.41, C92.42, C92.51
Drugs: micafungin
SMILES: CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

        A. patients belong to either A-1 or A-2 A-1. patients with newly diagnosed acute myeloid
        leukemia who approve to get induction chemotherapy with (cytarabine plus idarubicin) or
        (modified Fludarabine + cytarabine + idarubicin ) A-2. patients with newly diagnosed acute
        lymphoid leukemia who approve to get induction chemotherapy with VPDL (vincristine +
        prednisolone + daunorubicin + L-asparaginase), C-VPDL (cyclophosphamide + vincristine +
        prednisolone + daunorubicin + L-asparaginase), or (R)-hyperCVAD ((Rituximab) +
        cyclophosphamide + vincristine + Adriamycin + dexamethasone) B. Eastern Cooperative
        Oncology Group performance status score is equal to or more than 2 C. patients who
        voluntarily sign the agreement

        Exclusion Criteria:

        A. evidence of proven/probable/possible fungal infection within 30 days before induction
        chemotherapy B. hypersensitivity to echinocandin C. patients had other malignancy within 5
        years D. previous treatment history with chemotherapy, radiation therapy, or
        immunosuppressive therapy.

        E. pregnant or breast-feeding women F. immunodeficient patients including AIDS G. patients
        with uncontrolled seizure or psychiatric disorder H. clinically significant heart disorder
        (myocardial infarction within 3 months or left ventricular ejection fraction < 40%) I.
        interstitial lung disease J. previous organ transplantation history K. galactose
        intolerance L. patients who participated this study before.
Clinical trial NCT02440958 (phase 2, status: completed)
Conditions: pancreatic ductal adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: modified folfirinox regimen
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed pancreatic ductal adenocarcinoma (metastatic or locally
             advanced stage)

          -  Refractory or progress to Gemcitabine based 1st line chemotherapy

          -  Older than 19 years old and younger than 75 years old

          -  Life expectancy> 3 months

          -  ECOG Performance status ≤2

          -  Only patients with measurable lesions in imaging study

          -  Adequete BM function (WBC ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl,
             platelet count ≥ 100,000/µl)

          -  Adequete liver function (total bilirubin < 1.5 X the upper limits of normal (ULN), AST
             and ALT <3 X UNL, and alkaline phosphatases < 3 X ULN or < 5 x ULN in case of liver
             involvement)

          -  Adequete renal function (serum creatinine < 1.5 mg/dl)

          -  Adequete cardiopulmonary function

        Exclusion Criteria:

          -  Pathologically confirmed another type of pancreatic cancer (except ductal
             adenocarcinoma)

          -  Metastatic adenocarcinoma of originating at other organs

          -  Evidence with CNS metastasis

          -  Active infection

          -  Uncontrolled serious medical or psychiatric illness which can induce toxicity ro
             complication of treatment, such as inability to swallow, lacking physical integrity of
             the gastrointestinal tract, malabsorption syndrome, or active ulceration at upper
             gastrointestinal tract.

          -  Coexisting of other malignancies within 5 years, except squamous cell carcinoma and
             basal cell carcinoma of the skin

          -  Participation in any other investigational drug study within 1 month

          -  No signed informed consent
Clinical trial NCT02441283 (phase 2/phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: abt-493, abt-530
SMILES: CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC\C=C\C(F)(F)C2=NC3=C(C=CC=C3)N=C2O[C@@H]2C[C@H](N(C2)C1=O)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1, [H][C@](C)(OC)[C@]([H])(N=C(O)OC)C(=O)N1CCC[C@@]1([H])C1=NC2=C(N1)C=C(F)C(=C2)[C@@]1([H])CC[C@@]([H])(N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@]2([H])CCCN2C(=O)[C@@]([H])(N=C(O)OC)[C@@]([H])(C)OC)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          1. Participant is male or female 18 years of age or older

          2. Participant has received at least one dose of an ABT-493- and/or ABT- 530 containing
             regimen in a prior AbbVie hepatitis C virus (HCV) Phase 2 or 3 study

          3. The interval between the last dose of the AbbVie direct-acting antiviral agent (DAA)
             therapy from the previous clinical study and enrollment in Study M13-576 must be no
             longer than 2 years for subjects who have not been retreated. Participants who have
             been treated with a commercially available anti-HCV treatment may be enrolled greater
             than 2 years after the last dose of the AbbVie DAA therapy from the previous clinical
             study.

          4. Participant must voluntarily sign and date the informed consent form approved by an
             Independent Review Board or Ethics Committee prior to the initiation of any
             study-specific procedures.

          5. Participant completed the post-treatment period of an eligible prior study.

        Exclusion Criteria:

          1. The investigator considers the participant unsuitable for the study for any reasons
             (e.g., failure to comply with study procedures in the prior AbbVie clinical study).

          2. Receipt of any investigational HCV antiviral treatment after receiving ABT-493 and/or
             ABT-530 in the prior study.

          3. Participants who experienced non-virologic treatment failure due to premature
             discontinuation of study drug in prior study of ABT-493/ABT-530.

          4. Participation in AbbVie's Study M15-942 protocol for re-treatment for virologic
             failure in the prior Phase 2 or 3 study.
Clinical trial NCT02441946 (phase 2, status: completed)
Conditions: breast cancer, hormone receptor positive tumor, early-stage breast carcinoma
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, Z17.0, Z17.1, T47.0X6S, T50.7X6S, T47.0X3S, T47.0X4S, T47.0X5S, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: abemaciclib, loperamide, anastrozole
SMILES: CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1, O[Bi]1OC(=O)C2=CC=CC=C2O1, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Have postmenopausal status.

          -  Adenocarcinoma of the breast.

          -  Breast tumor ≥1 centimeter (cm) in diameter, HR+, HER2-.

          -  Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy.

          -  Primary breast cancer that is suitable for baseline core biopsy.

          -  Have adequate organ function.

        Exclusion Criteria:

          -  Bilateral invasive breast cancer.

          -  Metastatic breast cancer (local spread to axillary lymph nodes is permitted).

          -  Inflammatory breast cancer.

          -  Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in
             the same breast as currently being treated.

          -  Prior radiotherapy to the ipsilateral chest wall for any malignancy.

          -  Prior anti-estrogen therapy.
Clinical trial NCT02442687 (phase 2, status: completed)
Conditions: nonalcoholic steatohepatitis
ICD codes: K75.81
Drugs: jkb-121: 5 mg twice daily, jkb-121: 10 mg twice daily, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Provision of written informed consent

          3. Biopsy-proven NASH within 12 months or at screening

          4. ALT > 40 U/L for women and > 60 U/L for men at screening and at least once in the
             previous 12 months.

          5. HBA1C of ≤ 9.0

        Exclusion Criteria:

          1. Any chronic liver disease other than NASH

          2. Cirrhosis, as assessed clinically or histologically

          3. Presence of vascular liver disease

          4. BMI ≤ 25 kg/m2

          5. Excessive alcohol use (> 20 g/day) within the past 2 years

          6. AST or ALT > 250 U/L.

          7. Type 1 diabetes mellitus

          8. Bariatric surgery in the past 5 years.

          9. Weight gain of > 5% in past 6 months or > 10% change in past 12 months.

         10. Contraindication to MRI

         11. Inadequate venous access

         12. HIV antibody positive, hepatitis B surface antigen positive (HBsAg), or Hepatitis C
             virus (HCV) RNA positive.

         13. Receiving an elemental diet or parenteral nutrition

         14. Chronic pancreatitis or pancreatic insufficiency

         15. Any history of complications of cirrhosis

         16. Concurrent conditions:

               -  Inflammatory bowel disease

               -  Significant cardiac disease

               -  chronic infection or immune mediated disease

               -  Any malignant disease

               -  Prior solid organ transplant

               -  Any other concurrent condition which, in the opinion of the investigator, could
                  impact adversely on the subject participating or the interpretation of the study
                  data.

         17. Concurrent medications which may treat NASH

         18. HbA1C > 9.0%

         19. Pregnancy or breastfeeding.
Clinical trial NCT02443155 (phase 2, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: nnc0114-0006, liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  T1DM (type 1 diabetes mellitus) (as diagnosed clinically) for not more than 20 weeks
             prior to screening - Male or female, aged 18-45 (both inclusive) at the time of
             signing the informed consent form

          -  Non-fasting peak C-peptide higher or equal to 0.2 nmol/l at visit 2

          -  BMI (body mass index) higher or equal to 18.5 kg/m^2

          -  Presence of one or more islet specific auto antibodies (glutamic acid decarboxylase
             (GAD), islet antigen-2 (IA2) or zinc-transporter 8 (ZnT8)) at screening

          -  Insulin dependence unless in temporary spontaneous remission (honeymoon period)

        Exclusion Criteria:

          -  Daily insulin usage above 1 U/kg per day at screening or use of continuous
             subcutaneous insulin infusion (CSII)

          -  History of recurrent (e.g. several times a year) of severe (e.g. pneumonia) or chronic
             infections or conditions predisposing to chronic infections (e.g., bronchiectasis and
             chronic osteomyelitis)

          -  History of severe systemic fungal infection within the past 12 months prior to
             screening unless treated and resolved with appropriate documented therapy

          -  Vaccination within 4 weeks before randomisation, Visit 3 (V3)

          -  Receipt of any other concomitant medications or herbal products that can influence the
             immune system within 90 days prior to screening (V1)

          -  History of pancreatitis (acute or chronic)

          -  Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary
             Thyroid Carcinoma (MTC)

          -  Any past or current diagnosis of malignant neoplasms

          -  Known impairment of the immune system, except for T1DM, coeliac disease, alopecia,
             autoimmune antibodies not considered clinical important (e.g. thyroid antibodies
             without any clinically important thyroid disease), and vitiligo
Clinical trial NCT02445859 (phase 2, status: completed)
Conditions: surgical site infection
ICD codes: O86.09, O86.01, O86.02, T81.49XS, O86.03, T81.41XS, T81.42XS
Drugs: cefuroxime 4 hourly bolus
SMILES: [H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O
Eligibility criteria:

        Inclusion criteria

          -  Undergoing colorectal surgery (incision, excision or anastomosis of the large bowel,
             including anastomosis of small to large bowel)

          -  Age >18.

          -  Expected duration of surgery > 2hours

          -  Creatinine clearance > 40 ml/min

          -  Cefuroxime/metronidazole are appropriate antibiotic prophylaxis regimens.

          -  Patient capable of giving informed consent

          -  Patients undergoing colorectal surgery plus additional surgery e.g. plastic surgery,
             urological surgery, gynaecological surgery.

          -  If it is not possible to obtain intra-operative blood samples e.g. difficult vascular
             access, or pre-operative swabs e.g. anatomy makes it difficult to obtain, patients
             will be included and this information treated as missing data. Patients on antibiotic
             treatment for an existing infection (except SSIs) can be included in the study

        Exclusion Criteria:

          -  Unable to consent

          -  Pregnancy

          -  Expected duration of surgery <2hours

          -  Creatinine clearance <40ml/min

          -  Individual level microbiological advice for non cefuroxime based prophylaxis

          -  Cephalosporin allergy

          -  Penicillin allergy (hypersensitivity reaction only)

          -  Coumarin (warfarin and acenocoumarol) treatment

          -  Active blood borne virus infection e.g. HIV, hepatitis.

          -  Seizure history

          -  Concurrent use of probenecid

          -  Current participation in a research project aimed at reducing SSIs

          -  Antibiotics for treatment of a systemic Gram negative infection within 2 hours of
             initiation of surgery (Vancomycin, Teicoplanin, Daptomycin, Linezolid, Flucloxacillin.
             Nitrofurantoin and Clarithromycin would be permissible antibiotics without systemic
             Gram negative antibiotics).

          -  A current diagnosis of a SSI at the time of study entry.
Clinical trial NCT02446717 (phase 2/phase 3, status: completed)
Conditions: chronic hepatitis c, hepatitis c virus, hcv, direct-acting antiviral agent (daa)-experienced
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-493, abt-530, ribavirin (rbv), abt-493/abt-530
SMILES: [H][C@](C)(OC)[C@]([H])(N=C(O)OC)C(=O)N1CCC[C@@]1([H])C1=NC2=C(N1)C=C(F)C(=C2)[C@@]1([H])CC[C@@]([H])(N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@]2([H])CCCN2C(=O)[C@@]([H])(N=C(O)OC)[C@@]([H])(C)OC)C=C1F, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, [H][C@](C)(OC)[C@]([H])(N=C(O)OC)C(=O)N1CCC[C@@]1([H])C1=NC2=C(N1)C=C(F)C(=C2)[C@@]1([H])CC[C@@]([H])(N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@]2([H])CCCN2C(=O)[C@@]([H])(N=C(O)OC)[C@@]([H])(C)OC)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          1. Patients from 18 to 70 years in Arms A, B, and C; patients 18 years of age or older in
             Arms D and E.

          2. Previous treatment with DAA-containing regimen for chronic hepatitis C virus (HCV)
             infection resulting in either on-treatment virologic failure or post-treatment relapse

          3. Chronic HCV genotype (GT) 1, 4, 5, or 6-infection (GT4-6 in Arms D and E)

        Exclusion Criteria:

          1. History of severe, life-threatening or other significant sensitivity to any drug

          2. Female who is pregnant, planning to become pregnant during the study or breastfeeding;
             or male whose partner is pregnant or planning to become pregnant during the study

          3. Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol

          4. Positive for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus
             antibody (HIV Ab)

          5. Co-infection with more than one HCV genotype
Clinical trial NCT02447276 (phase 2/phase 3, status: completed)
Conditions: osteoarthritis, knee, osteoarthritis, hip
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30, M16.9, M16.0, M16.10, M16.11, M16.12, M16.30, M16.31
Drugs: regn475, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Body mass index ≤39

          2. Clinical diagnosis of OA of the knee or hip

          3. History of inadequate pain relief or intolerance to analgesics used for OA

          4. Moderate to severe pain in the index joint

          5. History of regular use of analgesic medications for OA pain

          6. Willing to discontinue current non-steroidal anti-inflammatory drug (NSAID) and opioid
             pain medications

        Key Exclusion Criteria:

          1. Other diseases that may involve index knee or hip, including inflammatory joint
             diseases, crystalline disease (gout or pseudogout), endocrinopathies, metabolic joint
             disease, lupus erythematosus, rheumatoid arthritis, joint infections, neuropathic
             disorders, avascular necrosis, Paget's disease, renal osteodystrophy or tumors

          2. History of osteonecrosis, destructive arthropathy (RPOA), hip dislocation, pathologic
             fractures, neuropathic joint arthropathy, knee dislocation or hip dislocation

          3. Trauma to the index joint in the 30 days before screening

          4. Active fibromyalgia, regional pain caused by lumbar or cervical compression with
             radiculopathy or other moderate to severe pain that may confound assessments or
             self-evaluation of the pain associated with OA

          5. Prior to the start of the study has received a recommendation for, or is scheduled for
             joint replacement surgery to be performed during the study period

          6. Presence of subchondral insufficiency fracture on screening films or MRI

          7. Received an intra-articular injection of hyaluronic acid in the affected index joint
             within 90 days prior to the screening visit

          8. Systemic (ie, oral or intramuscular) corticosteroids within 30 days prior to the
             screening visit. Intra-articular corticosteroids in the index joint within 12 weeks of
             the screening visit, or to any other joint within 30 days prior to the screening
             visit.

          9. History of autonomic neuropathy, diabetic neuropathy, or presence of clinically
             relevant peripheral neuropathy at the time of screening

         10. Women of childbearing potential who have a positive pregnancy test result, or who do
             not have their pregnancy test results at baseline

         11. Pregnant or breastfeeding women
Clinical trial NCT02447302 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: etrasimod, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Moderately to severely active ulcerative colitis defined as a 3-component Mayo Clinic
             score

          -  Evidence of colonic ulcerative colitis activity on endoscopy

        Exclusion Criteria:

          -  Within 30 days prior to randomization, receipt of any of the following for the
             treatment of underlying disease: Non-biologic therapies (eg, cyclosporine, tacrolimus,
             tofacitinib, thalidomide), a non-biologic investigational therapy or an approved
             non-biologic therapy in an investigational protocol

          -  Within 60 days prior to randomization, receipt of any of the following: Infliximab,
             adalimumab, golimumab, certolizumab or any other investigational or approved biologic
             agent

          -  Any prior exposure to natalizumab, efalizumab, or rituximab
Clinical trial NCT02449018 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease, copd
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: qbw251, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria: Must have a diagnosis of GOLD II-III chronic obstructive pulmonary
        disease (COPD); Must have clinical diagnosis of chronic bronchitis; Must be either a
        current smoker (smoked ≤ 1 pack per day on average for the last 3 months with at least a 10
        pack year smoking history) OR an ex-smoker with at least a 10 pack year smoking history;
        Exclusion Criteria: Must not be receiving chronic, daily, systemic steroids; Must not have
        severe emphysema (determined by HRCT); Must not have had a COPD exacerbation or respiratory
        tract infection requiring antibiotics or oral steroids or hospitalization within 6 weeks of
        screening; Must not be pregnant or nursing or a woman of child bearing potential; Other
        protocol-defined inclusion/exclusion criteria may apply